Patents by Inventor Sudhir Agrawal

Sudhir Agrawal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulation of immunostimulatory properties by small oligonucleotide-based compounds
    Publication number: 20100166805
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Application
    Filed: December 3, 2009
    Publication date: July 1, 2010
    Inventors: Sudhir Agrawal, Fu-Gang Zhu, Ekambar Kandimalla
  • IMMUNOSTIMULATORY OLIGONUCLEOTIDE MULTIMERS
    Publication number: 20100166736
    Abstract: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.
    Type: Application
    Filed: September 23, 2009
    Publication date: July 1, 2010
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Dong Yu
  • IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS COMPRISING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
    Publication number: 20100143328
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunostimulatory oligonucleotides according to the invention further comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Application
    Filed: October 21, 2008
    Publication date: June 10, 2010
    Inventors: Sudhir Agrawal, Dong Yu, Ekambar R. Kandimalla
  • Modulation of immunostimulatory properties by small oligonucleotide-based compounds
    Patent number: 7713535
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5? end.
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: May 11, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Fu-Gang Zhu, Ekambar R. Kandimalla
  • Modulation of Toll-Like Receptor 4 Expression by Antisense Oligonucleotides
    Publication number: 20100111936
    Abstract: Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR4. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR4. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR4 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR4 expression and for prevention or treatment of diseases wherein modulation of TLR4 expression would be beneficial are provided.
    Type: Application
    Filed: November 4, 2009
    Publication date: May 6, 2010
    Applicant: IDERA PHARMACEUTICALS, INC.
    Inventors: Mallikarjuna Putta, Ekambar Kandimalla, Lakshmi Bhagat, Daqing Wang, Dong Yu, Sudhir Agrawal
  • Modulation of Toll-Like Receptor 5 Expression by Antisense Oligonucleotides
    Publication number: 20100111937
    Abstract: Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR5. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR5. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR5 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR5 expression and for prevention or treatment of diseases wherein modulation of TLR5 expression would be beneficial are provided.
    Type: Application
    Filed: November 4, 2009
    Publication date: May 6, 2010
    Applicant: IDERA PHARMACEUTICALS, INC.
    Inventors: Ekambar Kandimalla, Mallikarjuna Putta, Lakshmi Bhagat, Daqing Wang, Dong Yu, Sudhir Agrawal
  • Modulation of Toll-Like Receptor 2 Expression By Antisense Oligonucleotides
    Publication number: 20100111935
    Abstract: Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR2. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR2. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR2 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR2 expression and for prevention or treatment of diseases wherein modulation of TLR2 expression would be beneficial are provided.
    Type: Application
    Filed: November 4, 2009
    Publication date: May 6, 2010
    Applicant: IDERA PHARMACEUTICALS, INC.
    Inventors: Lakshmi Bhagat, Ekambar Kandimalla, Mallikarjuna Putta, Daqing Wang, Dong Yu, Sudhir Agrawal
  • Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
    Patent number: 7709617
    Abstract: The invention provides optimized methods and compositions for enhancing the immune response caused by immunostimulatory compounds used for the treatment of disease such as, but not limited to, treatment of cancer, autoimmune disorders, asthma, respiratory allergies, food allergies and infectious diseases in a patient. The optimized methods according to the invention provide synergy between the therapeutic effects of immunostimulatory oligonucleotides and immunomer compounds in accordance with the invention, and the therapeutic effect of cytokine immunotherapy and/or chemotherapeutic agents and/or radiation.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: May 4, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Sudhir Agrawal
  • Use of Inhibitors of Toll-Like Receptors in the Prevention and Treatment of Hypercholesterolemia and Hyperlipidemia and Diseases Related Thereto
    Publication number: 20100098685
    Abstract: The invention provides the use of TLR inhibitors or a pharmaceutically acceptable derivative thereof, optionally in combination with one or more lipid lowering composition, cholesterol lowering composition, diuretics, non-steroidal anti-inflammatory compounds (NSAIDs), antibodies, antisense oligonucleotides, TLR agonists, TLR antagonists, peptides, proteins or gene therapy vectors or combinations thereof for the prevention or treatment of hypercholesterolemia and/or hyperlipidemia and/or diseases associated therewith.
    Type: Application
    Filed: October 6, 2009
    Publication date: April 22, 2010
    Applicant: IDERA PHARMACEUTICALS, INC.
    Inventors: Fu-Gang Zhu, Ekambar Kandimalla, Sudhir Agrawal
  • Oligonucleotide mediated specific cytokine induction and prophylaxis and treatment of viral infection in a mammal
    Patent number: 7700570
    Abstract: The invention provides new methods for modulating specific CMI-inducing cytokines in vivo. Such new methods result in stimulation of the cytokines IL-6, IL-12 MIP-1? and MCP without substantially inducing undesired cytokines. The methods according to the invention are based upon administration of oligonucleotides containing particular structural motifs which lead to specific cytokine induction.
    Type: Grant
    Filed: June 12, 2002
    Date of Patent: April 20, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Qiuyan Zhao
  • MODULATION OF MYELOID DIFFERENTATION PRIMARY RESPONSE GENE 88 (MYD88) EXPRESSION BY ANTISENSE OLIGONUCLEOTIDES
    Publication number: 20100092486
    Abstract: Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of MyD88. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding MyD88. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding MyD88 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating MyD88 expression and for prevention or treatment of diseases wherein modulation of MyD88 expression would be beneficial are provided.
    Type: Application
    Filed: August 7, 2009
    Publication date: April 15, 2010
    Inventors: Ekambar Kandimalla, Mallikarjuna Putta, Lakshmi Bhagat, Daqing Wang, Dong Yu, Sudhir Agrawal
  • Epidermal growth factor receptor antisense oligonucleotides
    Patent number: 7671035
    Abstract: Disclosed are synthetic oligonucleotides complementary to nucleic acids encoding epidermal growth factor and methods of their use.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: March 2, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar R. Kandimalla
  • MODULATION OF TOLL-LIKE RECEPTOR 8 EXPRESSION BY ANTISENSE OLIGONUCLEOTIDES
    Publication number: 20100047188
    Abstract: Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR8. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR8. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR8 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR8 expression and for prevention or treatment of diseases wherein modulation of TLR8 expression would be beneficial are provided.
    Type: Application
    Filed: August 3, 2009
    Publication date: February 25, 2010
    Inventors: Ekambar Kandimalla, Mallikarjuna Putta, Lakshmi Bhagat, Daqing Wang, Dong Yu, Sudhir Agrawal
  • MODULATION OF TOLL-LIKE RECEPTOR 7 EXPRESSION BY ANTISENSE OLIGONUCLEOTIDES
    Publication number: 20100041734
    Abstract: Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR7. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR7. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR7 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR7 expression and for prevention or treatment of diseases wherein modulation of TLR7 expression would be beneficial are provided.
    Type: Application
    Filed: August 3, 2009
    Publication date: February 18, 2010
    Inventors: Ekambar Kandimalla, Mallikarjuna Putta, Lakshmi Bhagat, Daqing Wang, Dong Yu, FuGang Zhu, Sudhir Agrawal
  • MODULATION OF TOLL-LIKE RECEPTOR 3 EXPRESSION BY ANTISENSE OLIGONUCLEOTIDES
    Publication number: 20100041735
    Abstract: Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR3. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR3 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR3 expression and for prevention or treatment of diseases wherein modulation of TLR3 expression would be beneficial are provided.
    Type: Application
    Filed: August 4, 2009
    Publication date: February 18, 2010
    Inventors: Ekambar Kandimalla, Mallikarjuna Putta, Lakshmi Bhagat, Daqing Wang, Dong Yu, Sudhir Agrawal
  • MODULATION OF TOLL-LIKE RECEPTOR 9 EXPRESSION BY ANTISENSE OLIGONUCLEOTIDES
    Publication number: 20100035967
    Abstract: Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR9. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR9. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR9 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR9 expression and for prevention or treatment of diseases wherein modulation of TLR9 expression would be beneficial are provided.
    Type: Application
    Filed: July 28, 2009
    Publication date: February 11, 2010
    Inventors: Ekambar Kandimalla, Mallikarjuna Putta, Lakshmi Bhagat, Daqing Wang, Dong Yu, FuGang Zhu, Sudhir Agrawal
  • Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
    Patent number: 7632822
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunomers according to the invention further comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunomodulatory oligonucleotide and having an accessible 5? end.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: December 15, 2009
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Lakshmi Bhagat, Dong Yu, Ekambar Kandimalla
  • Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
    Patent number: 7595305
    Abstract: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunomers according to the invention further comprise at least two oligonucleotides linked at their 3? ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunomodulatory oligonucleotide and having an accessible 5? end.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: September 29, 2009
    Assignee: Idera Pharmaceuticals
    Inventors: Sudhir Agrawal, Lakshmi Bhagat, Dong Yu, Ekambar Kandimalla
  • Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents
    Patent number: 7569554
    Abstract: The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: August 4, 2009
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Sudhir Agrawal, Daqing Wang, Lakshmi Bhagat, Dong Yu
  • Immunostimulatory oligonucleotide multimers
    Patent number: 7566702
    Abstract: The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.
    Type: Grant
    Filed: September 22, 2005
    Date of Patent: July 28, 2009
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Ekambar Kandimalla, Dong Yu